Biologicals in Uveitis

  • Bianka Sobolewska
  • Deshka Doycheva
  • Christoph Deuter
  • Manfred Zierhut


Biologicals are substances produced from living organisms such as recombinant proteins or antibodies, which target cytokines or cell surface receptors resulting in suppression of specific immune effectors potentially leading to ocular inflammatory diseases [45]. There are different classes of biologic agents, including anti-TNF agents, interferon, anti-IL agents, anti B-cell agents, and agents against specific cell surface antigens. All of these biologicals are used off-label in the treatment of ocular diseases. However, indications for considering treatment with biologic agents are primary inflammatory eye diseases refractory to corticosteroids and conventional immunosuppressive drugs. This chapter will bring an update for knowledge about the use of the biologic agents in the treatment of uveitis.


Juvenile Idiopathic Arthritis Anterior Uveitis Sympathetic Ophthalmia Intermediate Uveitis Ocular Inflammatory Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behçet’s disease. Jpn J Ophthalmol. 2007;51:191–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Adán A, Mesquida M, Llorenç V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:2627–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Al Rashidi A, Al Fowez A, Kangave D, et al. A long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab. Ocul Immunol Inflamm. 2013;21:468–74.CrossRefPubMedGoogle Scholar
  4. 4.
    Angeles-Han S, Flynn T, Lehman T. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol. 2008;35:1897–8.PubMedGoogle Scholar
  5. 5.
    Ardoin SP, Kredich D, Rabinovich E, et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol. 2007;144:844–9.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Arida A, Fragiadaki K, Giavri E, et al. Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41:61–70.CrossRefPubMedGoogle Scholar
  7. 7.
    Artornsombudh P, Gevorgyan O, Payal A, et al. Infliximab treatment of patients with birdshot retinochoroidopathy. Ophthalmology. 2013;120:588–92.CrossRefPubMedGoogle Scholar
  8. 8.
    Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest. 2005;128:1062e47.CrossRefGoogle Scholar
  9. 9.
    Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm. 2012;18:226–32.CrossRefGoogle Scholar
  10. 10.
    Becker MD, Heiligenhaus A, Hudde T, et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol. 2005;89:1254–7.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Bhat P, Castañeda-Cervantes RA, Doctor PP, et al. Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol. 2009;247:687–92.CrossRefPubMedGoogle Scholar
  12. 12.
    Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319–24.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335–9.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Brasnu E, Wechsler B, Bron A, et al. Efficacy of interferon-alpha for the treatment of Kaposi’s sarcoma herpesvirus-associated uveitis. Am J Ophthalmol. 2005;140:746–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Buggage RR, Levy-Clarke G, Sen HN. HNA double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet’s disease. Ocul Immunol Inflamm. 2007;15:63–70.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibodies therapy. Oncologist. 2008;13:725–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm. 2013;21:12–20.Google Scholar
  18. 18.
    Davatchi F, Shams H, Rezaipoor M, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis. 2010;13:246–52.CrossRefPubMedGoogle Scholar
  19. 19.
    Deuter CME, Kötter I, Günaydin I, et al. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26:786–91.CrossRefPubMedGoogle Scholar
  20. 20.
    Deuter CM, Kötter I, Günaydin I, et al. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906–13.CrossRefPubMedGoogle Scholar
  21. 21.
    Deuter CME, Zierhut M, Möhle A, et al. Long-term remissions after cessation of interferon alpha treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum. 2010;62:2796–805.CrossRefPubMedGoogle Scholar
  22. 22.
    Diaz-Lopis M, Salom D, Garcia-deVicuna C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–81.CrossRefGoogle Scholar
  23. 23.
    Dick AD, Forrester JV, Liversidge J, et al. The role of tumor necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23:617–37.CrossRefPubMedGoogle Scholar
  24. 24.
    Dobner BC, Maz R, Becker MD, et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97:134–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Doycheva D, Zierhut M, Blumenstock G, et al. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results. Br J Ophthalmol. 2014;98:523–8.CrossRefPubMedGoogle Scholar
  26. 26.
    El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology. 2002;109:2342–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res (Hoboken). 2011;63:307–8.CrossRefGoogle Scholar
  28. 28.
    Erkens RJ, Mostard RLM, Wijnen PAHM, et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250:713–20.CrossRefGoogle Scholar
  29. 29.
    Foeldvari I, Nielsen S, Kümmerle-Deschner J, et al. Tumor necrosis factor-α blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007;34:1146–50.PubMedGoogle Scholar
  30. 30.
    Foster SC, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121:437–40.CrossRefPubMedGoogle Scholar
  31. 31.
    Gallagher M, Quinones K, Cervantes-Castañeda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Graefes Arch Clin Exp Ophthalmol. 2009;247:687–92.62.CrossRefGoogle Scholar
  32. 32.
    Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet’s disease. Am J Ophthalmol. 2008;146:837–44.CrossRefPubMedGoogle Scholar
  33. 33.
    Guillaume-Czitrom E, Berger C, Pajot C, et al. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet’s disease. Rheumatology. 2007;46:1570–3.CrossRefPubMedGoogle Scholar
  34. 34.
    Hatemi G, Bang D, Bodaghi B, et al. EULAR recommendations for the management of Behçet’s disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2008;67:1656–62.CrossRefPubMedGoogle Scholar
  35. 35.
    Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53(8):1377–85.Google Scholar
  36. 36.
    Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50:1390–4.CrossRefGoogle Scholar
  37. 37.
    Iaccheri B, Androudi S, Bocci EB, et al. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm. 2010;18:223–5.CrossRefPubMedGoogle Scholar
  38. 38.
    Kempen JH, Gangaputra S, Daniel E. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol. 2008;146:802–12.PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Kempen JH, Daniel E, Dunn JPO, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:b2480.PubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    Kenawy N, Cleary G, Mewar D, et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249:297–300.CrossRefPubMedGoogle Scholar
  41. 41.
    Kotaniemi K, Saila H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol. 2011;5:1425–9.PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Kötter I, Günaydin I, Zierhut M, et al. The use of interferon alpha in Behcet’s disease: review of the literature. Semin Arthritis Rheum. 2004;33:320–38.CrossRefPubMedGoogle Scholar
  43. 43.
    Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423–31.PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:613–20.CrossRefPubMedGoogle Scholar
  45. 45.
    Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785–96.e3.CrossRefPubMedGoogle Scholar
  46. 46.
    Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? Arthritis Rhuem. 2007;56:3248–52.CrossRefGoogle Scholar
  47. 47.
    Mackensen F, Jakob E, Springer C, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol. 2013;156(3):478–86.e1.Google Scholar
  48. 48.
    Magli A, Forte R, Navarro P, et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2013;251:1601–6.CrossRefPubMedGoogle Scholar
  49. 49.
    Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis. 2010;69:400–8.PubMedCentralCrossRefPubMedGoogle Scholar
  50. 50.
    Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxford). 2011;50:593–7.CrossRefGoogle Scholar
  51. 51.
    Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012;20:18–26.CrossRefPubMedGoogle Scholar
  52. 52.
    Miserocchi E, Pontikaki I, Modorati G, et al. Rituximab for uveitis. Ophthalmology. 2011;118:223–4.CrossRefPubMedGoogle Scholar
  53. 53.
    Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for sever uveitis. OII. 2014;22:90–5.Google Scholar
  54. 54.
    Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun. 2003;21:283–93.CrossRefPubMedGoogle Scholar
  55. 55.
    Nussenblatt RB, Peterson JS, Foster CS, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology. 2005;112:764–70.CrossRefPubMedGoogle Scholar
  56. 56.
    Ohno S, Nakamura S, Hori S, et al. Efficacy, safety and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveitis. J Rheumatol. 2004;31:1362–8.PubMedGoogle Scholar
  57. 57.
    Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592–8.CrossRefPubMedGoogle Scholar
  58. 58.
    Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol. 2011;129:288–94.CrossRefPubMedGoogle Scholar
  59. 59.
    O’Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol. 2002;2:37–45.CrossRefPubMedGoogle Scholar
  60. 60.
    Pe’er J, Hochberg FH, Foster CS. Clinical review: treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm. 2009;17:299–306.CrossRefPubMedGoogle Scholar
  61. 61.
    Physicans Desk Reference. Montvale: Medical Economics Company; 2000. p. 2654–58, 2808–17.Google Scholar
  62. 62.
    Plskova J, Greiner K, Forrester JV. Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144:55–61.CrossRefPubMedGoogle Scholar
  63. 63.
    Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44:1411–5.CrossRefPubMedGoogle Scholar
  64. 64.
    Rudwaleit M, Rodevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68:696–701.PubMedCentralCrossRefPubMedGoogle Scholar
  65. 65.
    Sen HN, Levy-Clarke G, Faia LJ, et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol. 2009;148:696–703.e1.PubMedCentralCrossRefPubMedGoogle Scholar
  66. 66.
    Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet. 2001;358:295–6.CrossRefPubMedGoogle Scholar
  67. 67.
    Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res. 2011;63:612–8.CrossRefGoogle Scholar
  68. 68.
    Simonini G, Zannin ME, Caputo R, et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology. 2008;47:1510–4.CrossRefPubMedGoogle Scholar
  69. 69.
    Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane review. Cochrane Database Syst Rev. 2011;16:CD008794.Google Scholar
  70. 70.
    Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18–23.CrossRefPubMedGoogle Scholar
  71. 71.
    Sobaci G, Bayraktar Z, Bayer A. Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm. 2005;13:59–66.CrossRefPubMedGoogle Scholar
  72. 72.
    Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alph-2a in treatment of patients with Behçet’s uveitis refractory to conventional treatments. Ophthalmology. 2010;117:1430–5.CrossRefPubMedGoogle Scholar
  73. 73.
    Sobrin L, Huang JJ, Christen W, et al. Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol. 2008;126:186–91.CrossRefPubMedGoogle Scholar
  74. 74.
    Stübiger N, Kötter I, Zierhut M. Complete regression of retinal neovascularisation after therapy with interferon alfa in Behcet’s disease. Br J Ophthalmol. 2000;84:1437–8.Google Scholar
  75. 75.
    Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open- label, prospective trial. Br J Ophthalmol. 2013;97:481–6.CrossRefPubMedGoogle Scholar
  76. 76.
    Tappeiner C, Heinz C, Ganser G, et al. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol. 2012;39:1294–5.CrossRefPubMedGoogle Scholar
  77. 77.
    Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumor necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19–30.CrossRefPubMedGoogle Scholar
  78. 78.
    Tugal-Tutgun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet’s uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244:1692–5.CrossRefGoogle Scholar
  79. 79.
    Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum. 2005;52:2478–84.CrossRefPubMedGoogle Scholar
  80. 80.
    Tynjälä P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66:548–50.PubMedCentralCrossRefPubMedGoogle Scholar
  81. 81.
    Wendling D, Paccou J, Berthelot JM, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic disease. Semin Arthritis Rheum. 2011;41:503–10.CrossRefPubMedGoogle Scholar
  82. 82.
    Wroblewski K, Sen HN, Yeh S, et al. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol. 2011;46:322–8.PubMedCentralCrossRefPubMedGoogle Scholar
  83. 83.
    Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol. 2010;94:284–8.CrossRefPubMedGoogle Scholar
  84. 84.
    Yeh S, Wroblewski K, Buggage R, et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun. 2008;31:91–7.PubMedCentralCrossRefPubMedGoogle Scholar
  85. 85.
    Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow-up data from the Italian registry. J Rheumatol. 2013;40:74–9.CrossRefPubMedGoogle Scholar
  86. 86.
    Zierhut M, Abu El-Asrar AM, Bodaghi B, Tugal-Tutkun I. Therapy of ocular Behçet disease. Ocular Immunol Inflamm. 2014;22:64–76.CrossRefGoogle Scholar
  87. 87.
    Zulian F, Balzarin M, Falcini F, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62:821–5.CrossRefGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  • Bianka Sobolewska
    • 1
  • Deshka Doycheva
    • 1
  • Christoph Deuter
    • 1
  • Manfred Zierhut
    • 1
  1. 1.Centre of OphthalmologyUniversity of TuebingenTuebingenGermany

Personalised recommendations